Oct 09 2026 This Week in CardiologyListener feedback on POET II, sham control trials in atrial fibrillation, ICDs in HCM, and agenda laundering are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
POET II Response-Tailored or Standard-Duration ABX for Infectious Endocarditis
POET I Trial https://www.nejm.org/doi/10.1056/NEJMoa1808312POET II Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2607887
II PVI-SHAM-AF trial Back in the News
GAP-AF Trial https://www.ahajournals.org/doi/10.1161/circep.115.003337PVI-SHAM-AF Trial 10.1016/S0140-6736(26)01558-8 External LinkWhy Sham Studies Are a Sham in 2026 10.1016/j.hrthm.2026.09.056 External LinkThe Indispensable Role of Sham Controls in Evaluating Interventional Therapies 10.1016/j.hrthm.2026.10.001 External Link
III ICDs in HCM
I CDs for the Prevention of SCD in High-Risk Patients with HCM https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.078597ICDs in HCM: Editorial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.079687
IV Agenda Laundering
How Commercial “Agenda Laundering” Shapes Critical Care https://www.bmj.com/content/395/bmj-2026-100963
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
424|28M
